Thyroid Carcinoma, Version 2.2014
Robert Michael Tuttle, Robert I. Haddad, Douglas Wilmot Ball et al. · Journal of the National Comprehensive Cancer Network · 2014
These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.
Cited by 200 works. doi:10.6004/jnccn.2014.0169 Open-access PDF
Authors
- Robert Michael Tuttle
- Robert I. Haddad
- Douglas Wilmot Ball
- David R. Byrd
- Paxton Vandiver Dickson
- Quan‐Yang Duh
- Hormoz Ehya
- Megan R. Haymart
- Carl K. Hoh
- Jason P. Hunt
- Andrei H. Iagaru
- FOUAD R. KANDEEL
- Peter Andreas Kopp
- Dominick M. Lamonica
- William M. Lydiatt
- Judith Czaja McCaffrey
- Jeffrey F. Moley
- Lee L. Parks
- Christopher D. Raeburn
- John Andrew Ridge
References
- SEER Cancer Statistics Review, 1975-2003
- Cancer statistics, 2014
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
- Cancer statistics, 2011
- Management of a Solitary Thyroid Nodule
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- Cabozantinib in Progressive Medullary Thyroid Cancer